Stay updated with breaking news from Coherus Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023" report has been added to ResearchAndMarkets.com's offering. This...
/PRNewswire/ -- The "Global Anti TIGIT Antibody Clinical Trials & Companies Insight 2023" report has been added to ResearchAndMarkets.com's offering. This...
Analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) to report ($0.98) earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Coherus BioSciences’ earnings. The highest EPS estimate is ($0.83) and the lowest is ($1.13). Coherus BioSciences reported earnings per share of ($0.40) in the same quarter […]
Equities analysts expect Coherus BioSciences, Inc. (NASDAQ:CHRS – Get Rating) to post $56.08 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Coherus BioSciences’ earnings, with the lowest sales estimate coming in at $54.97 million and the highest estimate coming in at $57.19 million. Coherus BioSciences posted sales […]
Coherus BioSciences, Inc. (NASDAQ:NASDAQ:CHRS) Q1 2022 Earnings Conference Call May 05, 2022 04:30 PM ET Company Participants McDavid Stilwell - CFO Denny Lanfear - President, CEO, and...